Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for DYNE-251 in Duchenne muscular dystrophy. The expected timing is based on the latest available company guidance and may change.
07/29/26:- PDUFA remains January 21, 2027; potential U.S. launch remains Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.